RxDoctor Payments Data

Daniel Parenti, DO

Pulmonary Disease · Philadelphia, PANPI 1871594978

Payments from drug & device makers

$34,129in general payments, 2019–2025

Across 165 payments — averaging $206.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$32K
  • GSK$902
  • Verona Pharma, Inc.$283
  • Regeneron Healthcare Solutions, Inc.$230
  • Boehringer Ingelheim$220
  • Novartis$115
  • plus $264 from 6 others

What the payments were for

  • Speaking & faculty fees$29,40086%
  • Food & beverage$4,70614%
  • Education$230%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,129 in reported general payments places this provider in the 80th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$11,485
Medicare patients
40
Services billed
235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab51$169,874
Trelegy ElliptaFluticasone/Umeclidin/Vilanter150$113,147
FasenraBenralizumab14$82,695
Dupixent SyringeDupilumab12$53,039
Breztri AerosphereBudesonide/Glycopyr/Formoterol41$28,480
Spiriva RespimatTiotropium Bromide11$7,555
Breo ElliptaFluticasone/Vilanterol15$6,039
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,069
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate21$3,849
Albuterol Sulfate HfaAlbuterol Sulfate125$3,475
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$3,216
Montelukast Sodium72$623
Roflumilast12$599
Fluticasone Propionate17$147
Prednisone34$139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$902$124,255176 claims
AstraZenecaFasenra, Breztri Aerosphere$32,115$111,17555 claims
Boehringer IngelheimSpiriva Respimat$220$7,55511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →